Myriem Boufraqech

This study evaluates TR-107, a mitochondrial ClpP agonist, showing antitumor effects in ACC cell lines and organoids, with synergistic activity when combined with IGF-1R inhibitors.

This study identifies TAZ deficiency as synthetically lethal with BRAF inhibitors in anaplastic thyroid cancer, revealing a mechanism of resistance and a potential therapeutic target.

This study shows that targeting PDPK1 and BRAF V600E together is a potent therapy for anaplastic thyroid cancer, leading to tumor regression through synergistic signaling inhibition and apoptosis.

This study shows that combining BRAFV600E inhibition with ferroptosis induction synergistically kills anaplastic thyroid cancer cells by increasing iron and oxidative stress.

The paper identifies MPC1 as a key driver of PARP inhibitor resistance in NSCLC lung cancer through a metabolism-focused CRISPR screen.